Gentamicin 

Aminoglycoside antibiotic capable of translational readthrough

Phase of research

FDA-/EMA-approved for Other Purpose

How it helps

Restore CFTR Function

General information

Gentamicin is a broad-spectrum aminoglycoside antibiotic made from Micromonospora purpurea. It was approved for medical use in 1964 and is used to treat several types of bacterial infections, including bone infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, and sepsis. In relation to cystic fibrosis, our AIM tool found the data that gentamicin can help nonsense CFTR mutations, such as W1282X, G542X, R553X, and Y122X, by suppressing their premature termination signals, which leads to the expression of full-length CFTR protein at the cell membrane.

Gentamicin on PubChem
Gentamicin on DrugBank
Gentamicin on Wikipedia

Synonyms

gentamicin sulfate

Marketed as

N/A

Dietary sources

N/A

Structure image not available

C21H43N5O7

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del/W1282X
1 34.83
Link Tested on Impact factor Notes
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations humans 34.83
G542X
4 10.32
Link Tested on Impact factor Notes
Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. human cell cultures 4.67 NB54 has similar effect but is less toxic.
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. mice 3.30
Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. human cell cultures 28.14
Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. mice 5.16 Less effective and more toxic than amikacin.
G85E/W1282X
1 34.83
Link Tested on Impact factor Notes
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations humans 34.83
R553X
1 28.14
Link Tested on Impact factor Notes
Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. human cell cultures 28.14
W1282X
2 16.41
Link Tested on Impact factor Notes
Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. human cell cultures 4.67 Less effective than NB54, but more effective than paromomycin or NB30. More toxic than NB54 or NB30.
Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. human cell cultures 28.14
W1282X/3849+10KbC→T
1 34.83
Link Tested on Impact factor Notes
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations humans 34.83
W1282X/G542X
1 34.83
Link Tested on Impact factor Notes
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations humans 34.83
W1282X/W1282X
1 34.83
Link Tested on Impact factor Notes
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations humans 34.83
Y122X
1 3.28
Link Tested on Impact factor Notes
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study humans 3.28

Does not treat

Mutation Number of sources Average impact factor
F508del/F508del
1 34.83
Link Tested on Impact factor Notes
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. humans 34.83
G542X
1 3.28
Link Tested on Impact factor Notes
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study humans 3.28
G542X/F508del
1 4.67
Link Tested on Impact factor Notes
Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. human cell cultures 4.67 Only after a more extended treatment period.
R1162X
1 3.28
Link Tested on Impact factor Notes
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study humans 3.28
W1282X
1 3.28
Link Tested on Impact factor Notes
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study humans 3.28